DR6/TNFRSF21 Antibody (Abbvie patent anti-TNFRSF21) [Biotin]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28486B
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
ELISA, Flow Cytometry, Functional
Label
Biotin
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # Abbvie patent anti-TNFRSF21
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for DR6/TNFRSF21 Antibody (Abbvie patent anti-TNFRSF21) [Biotin]
Immunogen
TNFRSF21 / DR6 / CD358
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Applications for DR6/TNFRSF21 Antibody (Abbvie patent anti-TNFRSF21) [Biotin]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: DR6/TNFRSF21
Long Name
Death Receptor 6
Alternate Names
BM-018, CD358, TNFRSF21
Gene Symbol
TNFRSF21
Additional DR6/TNFRSF21 Products
Product Documents for DR6/TNFRSF21 Antibody (Abbvie patent anti-TNFRSF21) [Biotin]
Product Specific Notices for DR6/TNFRSF21 Antibody (Abbvie patent anti-TNFRSF21) [Biotin]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...